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Inhibition of mitosis is a validated treatment approach fornon-small cell lung cancer (NSCLC). Both paclitaxel and
docetaxel are approved by the Food and Drug Administration
for the treatment of NSCLC, and many additional agents are
currently being evaluated. The session began with Dr. Jim
Winkler from ARRAY Biopharma providing background on
mitotic inhibition. He broke the drugs into four categories,
including several agents that were discussed in individual
presentations (denoted by parentheses).
1. Microtubilin binders:
a. Taxanes (including nab-paclitaxel)
b. Epithelones (including ixabepilone)
c. Halichondrins (including eribulin)
2. Microtubulin enzyme inhibitors: this class was not dis-
cussed further during the session, but these agents
prevent spindle function, leading to mitotic arrest and
cell death. Because some of these enzymes are not
expressed in nerve cells, these agents could potentially
avoid the neuropathy seen with taxanes.1 Drugs in
development include ARQ 621, EMD 534085, and
LY2523355.
3. Mitosis checkpoint kinase inhibitors (including
LY2603618).
4. Mitosis enzymes inhibitors (including aurora kinase
inhibitors and polo-like kinase [PLK] inhibitors). These
kinases have overlapping but different functions.2
Summary of Presentations
Dr. Amir Onn presented data on nab-paclitaxel in
which paclitaxel is suspended in human serum albumin di-
luted in saline. Compared with cremaphor-based paclitaxel,
the infusion time is shorter and steroids or antihistamines are
not required (although recently, rare hypersensitivity reac-
tions have been reported). The drug is being evaluated in
many histologies and is approved by the Food and Drug
Administration for treatment of breast cancer. A phase III
trial in which carboplatin plus nab-paclitaxel was compared
with carboplatin plus cremaphor-based paclitaxel was pre-
sented at ASCO 2010.3 Despite a greater paclitaxel dose
intensity in the nab-paclitaxel arm, the safety profile was
generally more favorable. Response rate favored the nab-
paclitaxel group, particularly in patients with squamous cell
carcinoma (relative risk 1.67: confidence interval 1.26, 2.21).
Dr. David Spigel discussed the microtubule stabilizing
epithelone B analog ixabepilone. Xenograft data show the
ability of ixabepilone to overcome the resistance to taxanes
seen in tumors overexpressing III tubulin.4 Ixabepilone
demonstrated activity in taxane-resistant NSCLC in a phase II
trial.5 It has been tested as a single agent, in combination with
carboplatin, and in combination with bevacizumab. Never-
theless, a large phase II trial failed to show superiority of
carboplatin and ixabepilone compared with carboplatin and
paclitaxel, even in a subset of III tubulin-positive patients.
Dr. Joseph Aisner presented data on eribulin, a syn-
thetic analog of halichondrin B. Suppression of microtubule
polymerization and sequestration of tubulin into nonfunc-
tional aggregates is the proposed mechanism of action.6 A
phase IB trial in combination with carboplatin defined the
maximum tolerated dose as 1.1 mg/m2 before carboplatin
AUC 6. Responses were seen in prostate cancer and tonsillar
cancer patients. At the time of the presentation, the study was
in a dose expansion phase in chemotherapy-naive NSCLC
patients.7 Eribulin has also been studied in combination with
erlotinib and pemetrexed.
Dr. Philip Bonomi discussed inhibitors of aurora ki-
nases, serine threonine kinases that play key roles in mitosis.
Aurora kinase A functions include roles in centrosome func-
tion, mitotic spindle assembly, telomerase up-regulation and
ras, and nuclear factor-B activation. Inhibition leads to
mitotic delay, monopolar spindles, and chromosomal segre-
gation errors. MLN8237 and ENMD-0276 are Aurora kinase
A inhibitors in development. Aurora kinase B (AKB) asso-
ciates with centromeres and along chromosomes. AKB is
involved in the cytokesis process and associates with passen-
ger proteins, including survivin, borealin, and internal cen-
tromere protein. Inhibition leads to polyploidy, particularly
tetraploidy, and cell death. AZD1152 and GSK1070916A are
AKB inhibitors in development. Pan-aurora inhibitors in
development include PHA-739358, SNS-314, CYC116, PF-
03814735, AT9283, and AS703569. Toxicities include my-
elosupression and mucositis.
Dr. Quincy Chu discussed PLK inhibitors. PLK2 and
PLK3 are felt to have tumor suppressor qualities, but the
relevance of these proteins is less clear than PLK1, the focus
of the talk. PLK1 is a serine-threonine kinase overexpressed
in many malignancies, including NSCLC. PLK1 is expressed
throughout the cell cycle, but it is highest during M phase.
PLK1 maintains genomic stability during S phase and is
important for recovery from G2/M arrest because of DNA
damage. PLK1 negatively regulates the activity and stability
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of p53 through phosphorylation. PLK1 inhibition leads to
proteasome-mediated degradation. Preclinical synergy has
been shown with pemetrexed, gemcitabine, and cisplatin. Dr.
Chu specifically discussed BI 6727, a dihydropteridinone
derivative that binds the ATP-binding pocket. Nanomolar
range IC50 was seen, whereas there was no inhibition of 50
other kinases up to 10 M. In clinical trials, responses have
been seen with myelosuppression as the main toxicity.
Dr. Eric Westin discussed the development of
LY2603618, an ATP-competitive checkpoint kinase 1 inhib-
itor. In vitro, the agent impairs DNA synthesis, increases
DNA damage (via mitotic defects), and induces apoptosis. In
xenograft models, LY2603618 impedes tumor growth when
given in combination with pemetrexed. A phase I study
established 150 mg/m2 as the maximum tolerated dose along
with pemetrexed 500 mg/m2 every 3 weeks. LY2603618 was
given 1 week before the first dose of pemetrexed and then the
day after pemetrexed with each cycle. One partial response
was seen, and a phase II study in NSCLC is ongoing.
Future Directions
Several speakers specifically addressed future direc-
tions during their talks. Dr. Onn discussed the potential for
coadministration of tumor-penetrating peptides with nab-
paclitaxel8 and selecting patients based on sparc, a protein
that binds to albumin and has been considered as a potential
predictor of response.9 Dr. Aisner discussed a planned phase
III trial of eribulin and gemcitabine versus cisplatin and
gemcitabine. Dr. Chu discussed a planned randomized phase
II trial of BI 6727, pemetrexed, or the combination of the two
agents in second- or third-line NSCLC.
In this session, several agents in development were
reviewed. These agents act on the mitotic process, a proven
target for antineoplastic therapy. It will be important for the
development of these agents to evaluate the potential advan-
tages over available mitotic inhibitors. It is likely that patient
selection will hold a key to improving the therapeutic window
by enhancing efficacy and/or limiting toxicity.
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